Alopecia Areata and Dexamethasone Mini-Pulse Therapy: A Prospective Cohort Study on Real World Evidence and Factors Related to Successful Response

March 2022 in “ Journal of Clinical Medicine ”

Manuel Sánchez‐Díaz, Trinidad Montero‐Vílchez, Ahinoa Bueno‐Rodríguez, Alejandro Molina‐Leyva, Salvador Arias‐Santiago

dexamethasone mini-pulse therapy alopecia areata Severity Alopecia Tool SALT score oral minoxidil hypothyroidism AA dexamethasone minoxidil

From the encyclopedia

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Minoxidil →

An essential vasodilator with some anti-androgenic effects

Studysummary In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study evaluated the effectiveness and safety of dexamethasone mini-pulse therapy in 40 patients with alopecia areata (AA) who did not respond to topical treatments. Over 12 months, more than 50% of patients achieved a 50% reduction in the Severity Alopecia Tool (SALT) score at 9 months. The therapy was more effective for patients with a later onset of the disease and without hypothyroidism, while those with early onset or hypothyroidism had poorer responses. The combination with oral minoxidil did not enhance outcomes. Side effects were common, with weight gain and glycemic disorders being the most frequent, particularly at higher doses. The study concluded that mini-pulse dexamethasone is an effective treatment for AA, though not beneficial for all subgroups, and recommended further studies due to the small sample size.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

19 / 19 results

research Advanced Medical Therapies in the Management of Non-Scarring Alopecia: Areata and Androgenic Alopecia

14 citations , November 2020 in “International Journal of Molecular Sciences”

This review article summarizes the potential role of advanced medical therapies—using genes, cells, and/or tissue engineering—in treating various types of alopecia, by examining clinical research, basic studies, and ongoing trials.

research Oral Minoxidil Treatment for Hair Loss: A Review of Efficacy and Safety

59 citations , July 2020 in “Journal of The American Academy of Dermatology”

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

research Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata

23 citations , September 2019 in “Journal of The American Academy of Dermatology”

In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.

research Alopecia Areata: A Long-Term Follow-Up Study of 104 Patients

29 citations , March 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This study found that the severity, duration, and relapse rate of alopecia areata decreased with older age at onset, while relapses mostly occurred early and declined over time.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

research The Effectiveness of Oral Mini-Pulse Methylprednisolone in the Treatment of Alopecia Areata in Vietnam

4 citations , January 2019 in “Open Access Macedonian Journal of Medical Sciences”

In this study, oral mini-pulse methylprednisolone therapy for alopecia areata was reported to be effective and safe over 6 months, with 82.2% of patients recovering well and no adverse events observed.

research Treatment of Alopecia Areata: An Australian Expert Consensus Statement

95 citations , November 2018 in “Australasian journal of dermatology”

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

research Systemic Treatments for Alopecia Areata: A Systematic Review

41 citations , September 2018 in “Australasian journal of dermatology”

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

research Alopecia Areata: Treatment Options and Efficacy

182 citations , December 2017 in “Journal of the American Academy of Dermatology”

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

research Alopecia Areata: Overview and Insights from January 2018

290 citations , December 2017 in “Journal of The American Academy of Dermatology”

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

research Sequential High- And Low-Dose Systemic Corticosteroid Therapy For Severe Childhood Alopecia Areata

18 citations , January 2017 in “Journal der Deutschen Dermatologischen Gesellschaft”

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.

research SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss

44 citations , November 2016 in “Journal of The American Academy of Dermatology”

This article updates a diagnostic tool (SALT II) for assessing hair loss by adding more precise measurements of scalp surface area, particularly useful for various types of alopecia.

research Alopecia Areata and Health-Related Quality of Life: A Systematic Review and Meta-Analysis

128 citations , February 2016 in “British Journal of Dermatology”

This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.

research Intravenous Methylprednisolone Pulse Therapy in Severe Alopecia Areata

14 citations , January 2015 in “Indian journal of dermatology, venereology, and leprology”

This study found that methylprednisolone pulse therapy may be an effective treatment option for patients with severe multifocal alopecia areata, particularly those experiencing their first episode.

research Alopecia Areata: An Evidence-Based Treatment Update

72 citations , July 2014 in “American journal of clinical dermatology”

This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.

research A Comparison of the Efficacy, Relapse Rate, and Side Effects Among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata

97 citations , January 2006 in “Dermatology”

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.